Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Shionogi's S-588410?
S-588410 is a subunit vaccine commercialized by Shionogi, with a leading Phase II program in Non-Small Cell Lung Cancer. According...
Data Insights
S-588410 by Shionogi for Non-Small Cell Lung Cancer: Likelihood of Approval
S-588410 is under clinical development by Shionogi and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...